Pancreatic Safety of Sitagliptin in the TECOS Study.

Authors

John B Buse
M Angelyn Bethel
Jennifer B Green
Susanna R Stevens
Yuliya Lokhnygina
Pablo Aschner
Carlos Raffo Grado
Tsvetalina Tankova
Julio Wainstein
Robert Josse
John M Lachin, George Washington UniversityFollow
Samuel S Engel
Keyur Patel
Eric D Peterson
Rury R Holman

Document Type

Journal Article

Publication Date

2-1-2017

Journal

Diabetes are

Volume

40

Issue

2

DOI

10.2337/dc15-2780

Keywords

Acute Disease; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreatitis; Proportional Hazards Models; Risk Factors; Sitagliptin Phosphate; Treatment Outcome

Comments

This is an open access PubMed Central article.

APA Citation

Buse, J., Bethel, M., Green, J., Stevens, S., Lokhnygina, Y., Aschner, P., Grado, C., Tankova, T., Wainstein, J., Josse, R., Lachin, J., Engel, S., Patel, K., Peterson, E., & Holman, R. (2017). Pancreatic Safety of Sitagliptin in the TECOS Study.. Diabetes are, 40 (2). http://dx.doi.org/10.2337/dc15-2780

Peer Reviewed

1

Open Access

1